ArticleiScience2023
Oral metformin transiently lowers post-prandial glucose response by reducing the apical expression of sodium-glucose co-transporter 1 in enterocytes.
Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Effect of metformin on insulin resistance in adults with type 1 diabetes: a 26-week randomized double-blind clinical trial.Nature communications · 2025 · on this mapTrial
- Synergistic antidiabetic efficacy of dorzolamide and metformin: HPTLC quantification and biological evaluation.Scientific reports · 2026Article
- Article
- Novel mechanism whereby metformin improves glucose homeostasis: TXNIP-GLUT1 axis modulation enhances intestinal glucotonic effects.Experimental & molecular medicine · 2025Article
- New Perspectives on the Molecular Action of Metformin in the Context of Cellular Transduction and Adipogenesis.International journal of molecular sciences · 2025Review
- Aerobic Exercise and Metformin: A Dual Approach to Enhancing Glycemic Maintenance in Type 2 Diabetes Mellitus.Chonnam medical journal · 2025Review
- Article
- Review
- Understanding the action mechanisms of metformin in the gastrointestinal tract.Frontiers in pharmacology · 2024Review
- Metformin: update on mechanisms of action and repurposing potential.Nature reviews. Endocrinology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metformin (MET) is the most prescribed antidiabetic drug, but its mechanisms of action remain elusive. Recent data point to the gut as MET's primary target. Here, we explored the effect of MET on the gut glucose transport machinery. Using human enterocytes (Caco-2/TC7 cells)
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.